Drug class
N-acetylated amino-acid derivative; vestibular symptom-modulating agent
Mechanism of action
The mechanism is not established. Proposed actions include modulation of membrane potential in vestibular neuronal networks and support of central vestibular compensation; these mechanisms remain hypotheses.
General use cases
- Used in some countries for symptomatic treatment of vertigo and dizziness. Clinical efficacy evidence remains limited; a systematic review found no randomised controlled trials demonstrating efficacy through September 2018.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
